AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9241338 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane at 0.25 MAC (0.19%)
Number of subjects: 60
Study 9241338 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane at 0.5 MAC (0.37%)
Number of subjects: 60
Study 9241338 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane at 1.0 MAC (0.74%)
Number of subjects: 60
Study 8382899 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) 15,000 aXaU/day sc
Number of subjects: 36
Study 8382899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8382899 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 36
Study 2941291 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg ciprofloxacin (n = 85)
Number of subjects: 164
Study 2941291 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ciprofloxacin (n = 79)
Number of subjects: 164
Study 28353542 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally relevant cardiovascular health promotion intervention
Number of subjects: 0
Study 28353542 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 26892847 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) with discontinuation of mADM (n=128)
Number of subjects: 249
Study 26892847 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness-based cognitive therapy (MBCT) + maintenance antidepressant medication (mADM) (n=121)
Number of subjects: 249
Study 24913704 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Acupuncture (MA)
Number of subjects: 303
Study 24913704 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-Acupuncture (EA)
Number of subjects: 303
Study 24913704 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 303
Study 22337509 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-threshold spinal cord stimulation
Number of subjects: 10
Study 22337509 — intervention group
Group type: EXPERIMENTAL
Intervention: Supra-threshold spinal cord stimulation
Number of subjects: 10
Study 22337509 — intervention group
Group type: COMPARATOR
Intervention: No stimulation (control)
Number of subjects: 10
Study 20129568 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic periconditioning (RIPC)
Number of subjects: 96
Study 20129568 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPC and morphine
Number of subjects: 96
Study 20129568 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 18276895 — intervention group
Group type: EXPERIMENTAL
Intervention: Entity condition (fixed intelligence)
Number of subjects: 0
Study 18276895 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental condition (improvable intelligence)
Number of subjects: 0
Study 16868056 — intervention group
Group type: COMPARATOR
Intervention: Behavioral intervention promoting a diet with 28% energy from total fat, less than 8% from saturated fat, 9% or less from polyunsaturated fat, and less than 75 mg cholesterol per 1000 kcal.
Number of subjects: 354
Study 16868056 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 354
Study 12620262 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% VARIHES or ISOHES + 4% albumin (1:1)
Number of subjects: 29
Study 12620262 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 29
Study 12620262 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% VARIHES or ISOHES
Number of subjects: 29
Study 12620262 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% albumin
Number of subjects: 29
Study 10856147 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled indomethacin (50 mg/d)
Number of subjects: 38
Study 10856147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 9126694 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (1,000 mg iv every 8 hours)
Number of subjects: 215
Study 9126694 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin (900 mg every 8 hours) plus Tobramycin (5 mg/[kg.d] in three divided doses) iv
Number of subjects: 215
Study 9126694 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 215
Study 9126694 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin/tobramycin
Number of subjects: 215
Study 9126694 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 215
Study 1493841 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (15 mg) plus ethanol (peak blood concentration of 11 mmol.l‐1)
Number of subjects: 6
Study 1493841 — intervention group
Group type: COMPARATOR
Intervention: Temazepam alone
Number of subjects: 6
Study 1493841 — intervention group
Group type: COMPARATOR
Intervention: Ethanol alone
Number of subjects: 6
Study 1493841 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of temazepam and ethanol
Number of subjects: 6
Study 4065191 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg p.o.)
Number of subjects: 0
Study 4065191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29565752 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Project
Number of subjects: 20
Study 29565752 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational control group
Number of subjects: 20
Study 27092785 — intervention group
Group type: EXPERIMENTAL
Intervention: OFS + tamoxifen
Number of subjects: 86
Study 27092785 — intervention group
Group type: EXPERIMENTAL
Intervention: OFS + exemestane
Number of subjects: 86
Study 27092785 — intervention group
Group type: COMPARATOR
Intervention: tamoxifen alone
Number of subjects: 86
Study 24337589 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD-810
Number of subjects: 44
Study 24337589 — intervention group
Group type: COMPARATOR
Intervention: Taxotere
Number of subjects: 44
Study 22549656 — intervention group
Group type: EXPERIMENTAL
Intervention: MPK featuring a microprocessor‐controlled stance and swing phase (MPKA)
Number of subjects: 30
Study 22549656 — intervention group
Group type: COMPARATOR
Intervention: Mechanically controlled prosthesis
Number of subjects: 30
Study 22549656 — intervention group
Group type: EXPERIMENTAL
Intervention: MPK featuring a microprocessor‐controlled stance phase (MPKB)
Number of subjects: 30
Study 22549656 — intervention group
Group type: COMPARATOR
Intervention: Mechanical knee joint condition
Number of subjects: 30
Study 20855682 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with OSAS
Number of subjects: 59
Study 20855682 — intervention group
Group type: COMPARATOR
Intervention: Patients with severe OSAS
Number of subjects: 59
Study 18520792 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule-dependent low-dose paclitaxel for radiosensitization
Number of subjects: 27
Study 15869701 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic facial expressions
Number of subjects: 0
Study 15869701 — intervention group
Group type: COMPARATOR
Intervention: Single-static, multi-static, dynamic, and first-last modes
Number of subjects: 0
Study 12790886 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy (anteromesial temporal lobe resection)
Number of subjects: 64
Study 12790886 — intervention group
Group type: COMPARATOR
Intervention: Continued medical therapy
Number of subjects: 64
Study 12790886 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized neocortical resections
Number of subjects: 64
Study 10348786 — intervention group
Group type: EXPERIMENTAL
Intervention: AZ (5 mg/kg/day) alone (ALONE)
Number of subjects: 10
Study 10348786 — intervention group
Group type: COMPARATOR
Intervention: AZ (5 mg/kg/day) and ATQ (30 mg/kg/day) simultaneously (SIM)
Number of subjects: 10
Study 7554041 — intervention group
Group type: COMPARATOR
Intervention: Oral tamoxifen at 10 mg twice a day
Number of subjects: 5
Study 7554041 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous 4-OH-TAM at 0.5 mg/day
Number of subjects: 5
Study 7554041 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous 4-OH-TAM at 1 mg/day
Number of subjects: 5
Study 7554041 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous 4-OH-TAM at 1 mg/day to a large cutaneous area excluding the breasts
Number of subjects: 5
Study 7554041 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous 4-OH-TAM at 2 mg/day to a large skin area excluding the breasts
Number of subjects: 5
Study 1842981 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 0
Study 1842981 — intervention group
Group type: COMPARATOR
Intervention: Control (no steroid treatment)
Number of subjects: 0
Study 7041728 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of vasopressin (40 U/h)
Number of subjects: 60
Study 7041728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7041728 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of vasopressin
Number of subjects: 60
Study 31421033 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg
Number of subjects: 149
Study 31421033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 30045346 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of anti tubercular therapy (ATT)
Number of subjects: 100
Study 30045346 — intervention group
Group type: COMPARATOR
Intervention: 12 months of anti tubercular therapy (ATT)
Number of subjects: 100
Study 28282746 — intervention group
Group type: EXPERIMENTAL
Intervention: Performing the action (acting)
Number of subjects: 80
Study 28282746 — intervention group
Group type: COMPARATOR
Intervention: Observing the action
Number of subjects: 80
Study 26822982 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong Hearts, Healthy Communities
Number of subjects: 16
Study 26822982 — intervention group
Group type: COMPARATOR
Intervention: Strong Hearts, Healthy Women
Number of subjects: 16
Study 25539714 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic Voiding Programme (SVP)
Number of subjects: 413
Study 25539714 — intervention group
Group type: EXPERIMENTAL
Intervention: SVP plus supported implementation (SVP+)
Number of subjects: 413
Study 25539714 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 413
Study 25539714 — intervention group
Group type: EXPERIMENTAL
Intervention: SVP and SVP+ (combined)
Number of subjects: 413
Study 22506794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 57
Study 22506794 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied relaxation (AR)
Number of subjects: 57
Study 19166765 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 40
Study 19166765 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 40
Study 17059423 — intervention group
Group type: EXPERIMENTAL
Intervention: ART-123 (0.06 mg kg(‐1) for 30 min, once daily)
Number of subjects: 234
Study 17059423 — intervention group
Group type: COMPARATOR
Intervention: Heparin sodium (8 U kg(‐1) h(‐1) for 24 h)
Number of subjects: 234
Study 17059423 — intervention group
Group type: EXPERIMENTAL
Intervention: ART-123
Number of subjects: 234
Study 17059423 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 234
Study 15123532 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate 400 mg retard once a day
Number of subjects: 303
Study 15123532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 12575238 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 40
Study 12575238 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study 9514431 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal deliveries (number of deliveries)
Number of subjects: 144
Study 9514431 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal position at rest and during simulated defecation
Number of subjects: 144
Study 9514431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal nerve terminal motor latency
Number of subjects: 144
Study 7648243 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol
Number of subjects: 59
Study 7648243 — intervention group
Group type: COMPARATOR
Intervention: 50 mg atenolol
Number of subjects: 59
Study 2523665 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (1.25, 2.5, and 5.0 mg twice daily)
Number of subjects: 600
Study 2523665 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (monotherapy)
Number of subjects: 600
Study 66240 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxymorphone
Number of subjects: 0
Study 66240 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular oxymorphone
Number of subjects: 0
Study 66240 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 0
Study 31350753 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolyte beverage (EB) - kCal: 120, Na: 840 mg, K: 320 mg, Mg: 5 mg
Number of subjects: 9
Study 31350753 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolyte beverage (EB)
Number of subjects: 9
Study 31350753 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (PB) - kCal: 5, Na: 35 mg
Number of subjects: 9
Study 28165543 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine 100 mg/d + adefovir dipivoxil 10 mg/d
Number of subjects: 120
Study 28165543 — intervention group
Group type: COMPARATOR
Intervention: entecavir 0.5 mg/d
Number of subjects: 120
Study 26390898 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month program of exercise training and nutrition
Number of subjects: 32
Study 26390898 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin stimulation in NK-92 cells
Number of subjects: 32
Study 23362880 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding from day 1
Number of subjects: 100
Study 23362880 — intervention group
Group type: COMPARATOR
Intervention: Nil by mouth until day 3, then oral diet (Control)
Number of subjects: 100
Study 20621564 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Based Motivational Interviewing (NBMI)
Number of subjects: 112
Study 20621564 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (LIFE)
Number of subjects: 112
Study 19036067 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline fibrinogen
Number of subjects: 785
Study 19036067 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen at the start of a 6-month interval
Number of subjects: 785
Study 19036067 — intervention group
Group type: COMPARATOR
Intervention: Risk models with and without fibrinogen
Number of subjects: 785
Study 17853750 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture plus Madopa
Number of subjects: 60
Study 17853750 — intervention group
Group type: COMPARATOR
Intervention: Madopa (Control)
Number of subjects: 60
Study 15172920 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet and physical activity)
Number of subjects: 0
Study 11335704 — intervention group
Group type: EXPERIMENTAL
Intervention: H(2)(15)O-PET during Tower of London (TOL) task
Number of subjects: 2
Study 9549168 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (4 mg daily)
Number of subjects: 43
Study 9549168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 7522395 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF 10 micrograms/kg
Number of subjects: 2
Study 7522395 — intervention group
Group type: COMPARATOR
Intervention: G-CSF 5 micrograms/kg
Number of subjects: 2
Study 7522395 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide 4 g/m2 + G-CSF 5 micrograms/kg
Number of subjects: 2
Study 3139705 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-polysaccharide vaccine (23 volunteers)
Number of subjects: 47
Study 3139705 — intervention group
Group type: COMPARATOR
Intervention: Control preparation containing polysaccharides only (24 volunteers)
Number of subjects: 47
Study 3139705 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease (serogroup B serotype 15 meningococcal disease, 13 survivors)
Number of subjects: 47
Study 3139705 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent-phase sera from disease survivors
Number of subjects: 47
Study 29265454 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment (oral hygiene instructions + scaling and root planing using ultrasound and Gracey curettes)
Number of subjects: 90
Study 29265454 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral hygiene instructions + supragingival removal of plaque and calculus using ultrasound)
Number of subjects: 90
Study 27569442 — intervention group
Group type: COMPARATOR
Intervention: MAP (cisplatin 120 mg/m2, doxorubicin 37.5 mg/m2 on days 1 and 2, high-dose methotrexate 12 g/m2)
Number of subjects: 618
Study 27569442 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPIE (MAP plus high-dose ifosfamide 14 g/m2 and etoposide 100 mg/m2)
Number of subjects: 618
Study 27569442 — intervention group
Group type: COMPARATOR
Intervention: MAP
Number of subjects: 618
Study 27569442 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPIE
Number of subjects: 618
Study 25405132 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg elemental magnesium (as magnesium sulfate ‐MgSo4‐) daily for 3 months
Number of subjects: 54
Study 25405132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 22430217 — intervention group
Group type: EXPERIMENTAL
Intervention: HP cream (1.5% w/w hyperforin-rich extract)
Number of subjects: 20
Study 22430217 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 20
Study 20831681 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron 30 mg/day (15 mg twice per day)
Number of subjects: 46
Study 20831681 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two capsules per day)
Number of subjects: 46
Study 19083405 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (4 g/d for 2 years)
Number of subjects: 60
Study 19083405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17169938 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention group
Number of subjects: 80
Study 17169938 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational control group
Number of subjects: 80
Study 14560218 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 325 mg daily
Number of subjects: 21
Study 14560218 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (Clop) 75 mg daily
Number of subjects: 21
Study 14560218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (Cilo) 100 mg twice daily
Number of subjects: 21
Study 14560218 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA + Clop
Number of subjects: 21
Study 14560218 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA + Cilo
Number of subjects: 21
Study 14560218 — intervention group
Group type: EXPERIMENTAL
Intervention: Clop + Cilo
Number of subjects: 21
Study 14560218 — intervention group
Group type: EXPERIMENTAL
Intervention: Clop + ASA
Number of subjects: 21
Study 11762813 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus cyclophosphamide (OXAC)
Number of subjects: 177
Study 11762813 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus cyclophosphamide (CPC)
Number of subjects: 177
Study 9421356 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cyclophosphamide/methotrexate/S-fluorouracil (CMF) (n = 130)
Number of subjects: 277
Study 9421356 — intervention group
Group type: COMPARATOR
Intervention: No post-operative treatment (n = 147)
Number of subjects: 277
Study 9421356 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with CMF in women with p53-positive tumours
Number of subjects: 277
Study 9421356 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with CMF in women with p53-negative tumours
Number of subjects: 277
Study 8215478 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron plus hydroxyzine hydrochloride (Group G/H)
Number of subjects: 0
Study 8215478 — intervention group
Group type: COMPARATOR
Intervention: Granisetron alone (Group G)
Number of subjects: 0
Study 3691592 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (90 mg/day) + Propranolol (120 mg/day)
Number of subjects: 67
Study 3691592 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (120 mg/day)
Number of subjects: 67
Study 29911513 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID)
Number of subjects: 330
Study 29911513 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaemia
Number of subjects: 330
Study 29911513 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-deficiency anaemia (IDA)
Number of subjects: 330
Study 29911513 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary habits
Number of subjects: 330
Study 29911513 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of fruits and vegetables
Number of subjects: 330
Study 29911513 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's education
Number of subjects: 330
Study 28277352 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (25 mg every 8 hours) plus intravenous infusion of 2 L isotonic solution
Number of subjects: 184
Study 28277352 — intervention group
Group type: COMPARATOR
Intervention: Hydration alone (control)
Number of subjects: 184
Study 25816382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient ED environment
Number of subjects: 70
Study 25816382 — intervention group
Group type: COMPARATOR
Intervention: Traditional ED environment
Number of subjects: 70
Study 24156455 — intervention group
Group type: EXPERIMENTAL
Intervention: Ademetionine 1, 4-butanedisulfonate combined with polyene phosphatidyl choline
Number of subjects: 62
Study 24156455 — intervention group
Group type: COMPARATOR
Intervention: Compound glycyrrhizin
Number of subjects: 62
Study 21914628 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 431
Study 21914628 — intervention group
Group type: COMPARATOR
Intervention: Infliximab to Abatacept
Number of subjects: 431
Study 19016987 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic saphenous vein harvest (EVH)
Number of subjects: 120
Study 19016987 — intervention group
Group type: COMPARATOR
Intervention: Conventional open saphenous vein harvest (OVH)
Number of subjects: 120